Effective June 1, SIGA will drive international promotion activities for oral TPOXX while maintaining its contractual relationship with Meridian to maintain continuity for key customer relationships. This amendment, which extends the term of the promotion agreement by two years with respect to specific territories including the European Union, gives SIGA primary responsibility for promoting oral TPOXX. Certain existing contracts under the promotion agreement, including Meridian's contract with the European Commission's DG Health Emergency Preparedness and Response Authority (HERA), will remain in effect.
SIGA Technologies Enters Amendment To Its International Promotion Agreement With Meridian Medical
The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.